Allarity Therapeutics, Inc. Derivative, Fair Value, Net
Allarity Therapeutics, Inc. (ALLR) had Derivative, Fair Value, Net of -$2.66 million as of 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Notes › Derivative Instruments and Hedging Activities › Derivative Instrument Detail
us-gaap:DerivativeFairValueOfDerivativeNet · last filed 2024-05-14
- 2024-03-31: Derivative, Fair Value, Net -$2.66M.
- 2023-12-31: Derivative, Fair Value, Net -$3.08M.
- 2023-09-30: Derivative, Fair Value, Net -$7.88M.
- 2023-06-30: Derivative, Fair Value, Net $1.14M.
| Period end | Derivative, Fair Value, Net | Derivative, Fair Value, Net as first filed |
|---|---|---|
| 2024-03-31 | -$2.66M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$3.08M 10-Q · filed 2024-05-14 | |
| 2023-09-30 | -$7.88M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $1.14M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $1.11M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$374.00K 10-K · filed 2024-03-08 | $1.08M 10-K · filed 2023-03-13 |
| 2022-09-30 | $1.06M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $1.03M 10-Q · filed 2022-10-07 | |
| 2022-03-31 | $1.00M 10-Q · filed 2022-05-27 | |
| 2021-12-31 | $979.00K 10-K · filed 2023-03-13 | |
| 2021-09-30 | $954.00K 10-Q/A · filed 2022-05-17 | |
| 2020-12-31 | $880.00K 10-Q/A · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |